Format

Send to

Choose Destination
J Cell Commun Signal. 2019 Jun;13(2):163-177. doi: 10.1007/s12079-018-00503-5. Epub 2019 Jan 21.

PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40).

Author information

1
Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, 560066, India.
2
Center of Excellence in Translational Medicine (CEMT) &Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile.
3
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
4
Insilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, Baltimore, MD, 21218, USA.
5
Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
6
Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India.
7
School of Biotechnology, KIIT (Deemed to be University), Bhubaneswar, Odisha, 751024, India.
8
Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA.
9
Department of Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II, 5M05C, Baltimore, MD, 21231, USA.
10
Lab Surgpath, Mumbai, Maharashtra, 400034, India.
11
Centre for Genomics, Molecular and Human Genetics, Jiwaji University, Gwalior, 474011, India.
12
School of Studies in Zoology, Jiwaji University, Gwalior, 474011, India.
13
Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, 560029, India.
14
NIMHANS-IOB Proteomics and Bioinformatics Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, 560029, India.
15
Department of Pathology, Millenium Institute on Immunology and Immunotherapy (IMII), Pontificia Universidad Católica de Chile, Santiago, Chile.
16
Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
17
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
18
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
19
Department of Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II, 5M05C, Baltimore, MD, 21231, USA. eizumch1@jhmi.edu.
20
Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, 560066, India. aditi@ibioinformatics.org.
21
Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India. aditi@ibioinformatics.org.

Abstract

Gallbladder cancer (GBC) is a rare malignancy, associated with poor disease prognosis with a 5-year survival of only 20%. This has been attributed to late presentation of the disease, lack of early diagnostic markers and limited efficacy of therapeutic interventions. Elucidation of molecular events in GBC can contribute to better management of the disease by aiding in the identification of therapeutic targets. To identify aberrantly activated signaling events in GBC, tandem mass tag-based quantitative phosphoproteomic analysis of five GBC cell lines was carried out. Proline-rich Akt substrate 40 kDa (PRAS40) was one of the proteins found to be hyperphosphorylated in all the invasive GBC cell lines. Tissue microarray-based immunohistochemical labeling of phospho-PRAS40 (T246) revealed moderate to strong staining in 77% of the primary gallbladder adenocarcinoma cases. Regulation of PRAS40 activity by inhibiting its upstream kinase PIM1 resulted in a significant decrease in cell proliferation, colony forming and invasive ability of GBC cells. Our results support the role of PRAS40 phosphorylation in GBC cell survival and aggressiveness. This study also elucidates phospho-PRAS40 as a clinical marker in GBC and the role of PIM1 as a therapeutic target in GBC.

KEYWORDS:

Cell survival; Gastrointestinal cancer; Phosphoproteomics; SGI-1776; Targeted therapy; mTOR signaling

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center